Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a "hold" rating on the stock.
Separately, JMP Securities restated a "market outperform" rating and issued a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.
Read Our Latest Analysis on DBV Technologies
DBV Technologies Stock Up 6.8 %
NASDAQ:DBVT opened at $5.21 on Friday. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $8.46. The business has a 50 day moving average price of $4.34 and a two-hundred day moving average price of $3.82. The company has a market cap of $107.16 million, a P/E ratio of -1.16 and a beta of 0.71.
Institutional Trading of DBV Technologies
A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Institutional investors own 71.74% of the company's stock.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
